Unclaimed brand
Improving the earlier detection of aggressive prostate cancer and urologic diseases with personalized molecular diagnostic solutions Learn more Recent Webinars https://youtu.be/N_Wq2NDi7yw?si=AMdqaCYLu5Ef8RsJ From Genomics to Risk Scores: Integrating GPS mdx Across CAPRA-Based Clinical Decision-Making Following an overview of the study, an expert panel will share cross-institutional perspectives on the clinical utility and real-world application of GPS […]
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#CE8F5A
Antique Brass
206, 143, 90
27, 54, 58
0, 31, 56, 19
#2D2D2D
Mine Shaft
45, 45, 45
0, 0, 18
0, 0, 0, 82
#EBEBEA
Desert Storm
235, 235, 234
60, 2, 92
0, 0, 0, 8
It develops personalized testing solutions that help clinicians assess cancer risk, support treatment decisions, and plan patient care. Its prostate cancer portfolio includes Exo mdx, a urine-based test with at-home collection available that can help guide decisions about whether a patient should have a prostate biopsy; Confirm mdx, which analyzes tissue from a prior negative biopsy to address sampling error and the possibility of missed cancer; and GPS mdx, a tissue-based genomic assay for men with localized prostate cancer that helps inform risk assessment and treatment choices. For infectious disease, mdxhealth offers Resolve mdx.
The company provides information and support for both physicians and patients, including access to test resources, representative contacts, physician portals, report access, and billing assistance. It also shares educational webinars and clinical information on how its tests may be used alongside other assessment methods
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
